Everard Munting, President of EUROSPINE, explains why sharing knowledge about spinal treatments on a global scale is the most effective way to develop best practice and enable early interventions.
The US based vaccine appears to be 96.4% effective against the original COVID mutation, with 86% efficacy against the UK variant and only 55% against the South African variant.
The 'London patient' joins the 'Berlin patient' as the second person in history to be cured of HIV, which is achieved via transplant of rare HIV-resistant stem cells.
Here, we learn how solutions-based organisation OPEX are simplifying the often daunting and complex digitisation process of healthcare records to vastly benefit the NHS.
A new report by the Public Accounts Committee found that the UK Test and Trace strategy, costing roughly £37 billion over two years, failed to ever meet 24 hour test result deadlines.
According to new data, COVID care home deaths in the United States are influenced by race - with majority non-White care homes experiencing 3.3 times more deaths.
A new medical education programme for diabetes healthcare providers in the UK is focusing on upskilling the knowledge and training of diabetes management technologies & devices.
Arun Swaminathan MD, Assistant Professor of Neurology and Epilepsy at the University of Nebraska Medical Center, considers the importance of improving infrastructure and management of epilepsy research.
Researchers at Yale believe that blood tests could predict severe or critical COVID cases, because blood holds a series of interesting biological signals about a person.
The UK has found six confirmed cases of the Brazilian COVID mutation yesterday (28 February) - but an individual who tested positive three weeks ago is still being traced throughout the country.
New data suggests that before 60 days of COVID symptoms beginning is the best window for convalescent plasma donation - which is how antibodies were created in countless COVID-19 patients before vaccines.
The Government unveiled the confirmed priority groups for phase two of UK vaccinations - the Joint Committee on Vaccination and Immunisation (JCVI) is choosing age as the deciding factor.
